Literature DB >> 19714537

Enlarging clinical spectrum of FALS with TARDBP gene mutations: S393L variant in an Italian family showing phenotypic variability and relevance for genetic counselling.

Paola Origone1, Claudia Caponnetto, Monica Bandettini Di Poggio, Elisabetta Ghiglione, Emilia Bellone, Giovanna Ferrandes, Giovanni Luigi Mancardi, Paola Mandich.   

Abstract

OBJECTIVE: The present study was aimed to enlarge the Italian ALS sample analysed for TARDBP gene mutations.
METHODS: Genomic DNA from 47 patients, 70 FTD patients and 158 controls was extracted from peripheral blood samples according to a standard protocol. The five coding exons (2-6) of the TARDBP gene and the flanking exon-intron boundaries were analysed by direct sequencing. Using ClustalW2 human TDP-43, protein sequence was aligned with TDP-43 protein sequence of different species.
RESULTS: A heterozygous c.1178 C-->T transition that leads to a change p.S393L was observed in a 75-years-old male patient and in his two affected siblings. A patient's brother had died at 69 years of age after a two-year history of ALS. In FTD patients no mutations were found.
CONCLUSIONS: We describe a further Italian family with FALS, in which a variant (p.S393L) of the TARDBP gene was identified. Clinical course and phenotypic variability in three affected siblings is presented and relevance for genetic counselling of patients and their families is underlined. At the present state of knowledge, we suggest that the same guidelines established for SOD1 molecular testing could be proposed also for TARDBP analysis in FALS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19714537     DOI: 10.3109/17482960903165039

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  15 in total

Review 1.  RNA processing pathways in amyotrophic lateral sclerosis.

Authors:  Marka van Blitterswijk; John E Landers
Journal:  Neurogenetics       Date:  2010-03-27       Impact factor: 2.660

Review 2.  Clinical genetics of amyotrophic lateral sclerosis: what do we really know?

Authors:  Peter M Andersen; Ammar Al-Chalabi
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

3.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

Review 4.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

Review 5.  The complex molecular biology of amyotrophic lateral sclerosis (ALS).

Authors:  Rachel L Redler; Nikolay V Dokholyan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 6.  TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43.

Authors:  Tania F Gendron; Rosa Rademakers; Leonard Petrucelli
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 7.  FTD and ALS: a tale of two diseases.

Authors:  R Ferrari; D Kapogiannis; E D Huey; P Momeni
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

Review 8.  The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum.

Authors:  Tim Van Langenhove; Julie van der Zee; Christine Van Broeckhoven
Journal:  Ann Med       Date:  2012-03-16       Impact factor: 4.709

9.  Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins.

Authors:  Shoji Watanabe; Kumi Kaneko; Koji Yamanaka
Journal:  J Biol Chem       Date:  2012-12-12       Impact factor: 5.157

Review 10.  TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets.

Authors:  Emma L Scotter; Han-Jou Chen; Christopher E Shaw
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.